Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2014

View Archived Issues

Safety issues noted in phase I study of cabazitaxel in gastric adenocarcinoma

The Vanderbilt University patents novel mGlu5 receptor modulators

Lanreotide autogel/depot reduces carcinoid syndrome rescue therapy in ELECT trial

Simtuzumab well tolerated in phase I and II trials

Nektar Therapeutics reviews product development status for 2014

Preliminary trial results provided for selinexor in colorectal cancer

Hybrigenics achieves first milestone under USP collaboration

Novel antibodies for cancer presented by Regeneron Pharmaceuticals

4SC Discovery discloses new casein kinase inhibitors

French and Danish researchers patent new K(Ca)3.1 channel blockers

Cystadane approved in Japan for homocystinuria

A team in Israel divulges new anti-fibrinolytic compositions for coagulation

Roche and Genentech synthesize new pim kinase inhibitors

Amarin to appeal FDA's rescindment of ANCHOR SPA agreement

Novartis synthesizes new agents for macular degeneration and other disorders

Phase I study begins for hemophilia candidate ALN-AT3SC

Pluristem's phase I/II trial of PLX-PAD cells in muscle injury meets primary endpoints

New radioligands tested for assessment of AD in living subjects

GSK launches phase I trial of GSK-2879552 in relapsed/refractory SCLC

First trials in phase III bitopertin program miss primary endpoints

Novartis opens phase II study of VAY-736 in multiple sclerosis

Eculizumab receives FDA orphan drug designation for delayed graft function in renal transplantation

French authorities grant temporary authorization for use of Raxone in LHON

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...